26 citations
,
October 2018 in “Clinical & Translational Oncology” This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.
44 citations
,
September 2015 in “Annals of Oncology” This study reported that targeted anticancer therapies are associated with an increased risk of alopecia compared to placebo, although the risk was lower compared to chemotherapy.
44 citations
,
November 2022 in “Frontiers in Immunology” This review discusses the role of toll-like receptors in cancer treatment, providing an overview of pre-clinical studies and clinical trials on TLR-targeted therapies and noting the challenges and future prospects.
278 citations
,
May 2013 in “Ca” This review discusses the shift in toxicity profiles of cancer therapies from traditional chemotherapy to targeted agents, noting similar overall toxicities but with different side effects, and reports no new findings.
26 citations
,
February 2015 in “Pediatric blood & cancer” This study analyzed 19 clinical trials and found that dermatologic adverse events, such as rash, xerosis, and mucositis, frequently occur in pediatric patients receiving targeted anticancer therapies.
